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New risk factors of severe hypoglycemia
The number of elderly persons is increas-
ing dramatically worldwide, especially in
East Asia, and the average age of patients
with diabetes has become older in this
area. The quality of life of elderly patients
with diabetes is easily impaired because
of frailty and the development of physical
disability. One of the major causes of
these conditions is treatment-related sev-
ere hypoglycemia, which becomes a trig-
ger for incidental falls, irreversible brain
damage, cognitive dysfunction, cardiovas-
cular events and fetal arrhythmia. There-
fore, identifying the risk factors of severe
hypoglycemia is critical for predicting
and preventing severe hypoglycemia and
its complications in individual patients.
Various studies have investigated the risk
factors for severe hypoglycemia, and have
identified the type of diabetes, aging, sul-
fonylureas, insulin therapy, low glycated
hemoglobin (HbA1c) values, long dura-
tion of diabetes and poor cognitive func-
tion as risk factors. A recent survey of
the Japan Diabetes Society regarding
treatment-related severe hypoglycemia
confirmed that severe hypoglycemia was
associated with old age, low glycated
hemoglobin, medication of insulin and/or
sulfonylureas, renal dysfunction, and a
prior history of severe hypoglycemia in
Japanese patients with type 2 diabetes1.
Lee et al.2 recently evaluated the risk
factors for severe hypoglycemia in the
Atherosclerosis Risk in Communities
(ARIC) Study. The ARIC study is a
prospective study that has been carried
out since 1987–1989 in four USA com-
munities. After 12 years of the study,
1,144 black and white individuals out of
a total of 1,511 individuals who were
diagnosed as diabetes or were taking dia-
betes medications were prospectively
observed during a median follow-up per-
iod of 15.2 years. A total of 185 severe
hypoglycemic events were identified
through 2013 by International Classifica-
tion of Diseases ninth revision codes
from claims for hospitalization, emer-
gency department visits and ambulance
use. The Cox regression analysis showed
that old age, black race, high fruc-
tosamine level, glucose-lowering medica-
tion, >300 mg/g urinary albumin
excretion rate and poor cognitive func-
tion were identified as the isolated tradi-
tional risk factors of severe
hypoglycemia. In addition to these fac-
tors, activities of daily living (ADLs) diffi-
culty and the number of ADLs, but not
instrumental ADLs (IADLs), were associ-
ated with severe hypoglycemia. As IADLs
might be tightly associated with recogni-
tion function, the difficulty of IADLs was
not solely determined as a risk factor of
severe hypoglycemia after adjustment of
cognitive function (Figure 1)2.
The Atherosclerosis Risk in Commu-
nities study also showed that low
1,5-anhydroglucitol (1,5-AG) was a risk
factor for severe hypoglycemia indepen-
dent of average glucose levels (Fig-
ure 1)2. Hyperglycemia-induced increase
of urinary glucose levels compete re-
absorption of 1,5-AG via urinary tract
and decrease serum 1,5-AG levels.
Therefore, low 1,5-AG, a biomarker of
glucose excursion, which reflects a long
duration of high-glucose excursion,
could be related to overtreatment for
hyperglycemia and cause easily hypo-
glycemia. Indeed, higher HbA1c tended
to be a risk factor for severe hyper-
glycemia, as well as lower HbA1c levels
in type 2 diabetes patients3. The Dia-
betes Control and Complication Trial
also reported that glucose variability
determined from a standard deviation of
a 7-point self-monitoring glucose mea-
surement was associated with severe
hypoglycemia in the intensive insulin
treatment group for type 1 diabetes4.
In 2016, the Japan Diabetes Society
and the Japan Geriatrics Society recom-
mended that the target level of glycemic
control for elderly patients with diabetes
should be changed from <7–8.5%
according to the level of impaired cogni-
tive function and difficulty of ADLs and
IADLs with or without the use of insulin,
sulfonylureas or glinides5. In addition,
the lower limit of the target HbA1c level
for these patients should range between
6.5 and 7.5% to prevent severe hypo-
glycemia. This recommendation was
strongly confirmed by the results of the
ARIC study and the Survey of Severe
Hypoglycemia by the Japan Diabetes
Society1. Therefore, the level of cognitive
function and difficulty of ADLs should
be evaluated routinely, and the target of
glycemic goal should be decided accord-
ing to these parameters and well-known
traditional risks of severe hypoglycemia.
The recent development of oral glucose
medications, insulin analogs and insulin
devices could contribute to a decrease in
severe hypoglycemia. Among these devel-
opments, a predictive low glucose man-
agement system, which stops the insulin
delivery of a insulin pump if hypoglycemia
is predicted within a certain period, has
recently been reported to reduce severe
hypoglycemia in patients with type 1 dia-
betes6. On the contrary, high-risk patients
with diabetes for severe hypoglycemia are
increasing because of increasing number
of elderly patients with impaired recogni-
tion function, difficulty of ADL renal
dysfunction, and polypharmacy. We,
therefore, evaluate these risk factors totally
and select anti-diabetic medications with
lower risk for hypoglycemia in each
patient.
In conclusion, the ARIC study showed
that glucose fluctuations and the level of
ADLs could be associated with the inci-
dence of severe hypoglycemia, as well as
traditional risk factors, such as aging,
black race, averaged glucose level (fruc-
tosamine), diabetes medication, albumin-
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to-creatinine ratio and cognitive function.
These findings are very important for
determining the target glucose level and
to adequately select antidiabetic medica-
tion for individual elderly patients with
type 2 diabetes.
DISCLOSURE
Munehide Matsuhisa received speaker
fees (Sanofi K. K., Novartis Pharma K.K.,
Novo Nordisk Co., Ltd., Mitsubishi
Tanabe Corporation, Astellas Pharm Inc.,
Takeda Pharmaceutical Co., Ltd., Nippon
Eli Lilly Japan K.K.) and clinical research
grants (funding for clinical trials, clinical
studies, contracted research and collabo-
rative research; Daiichi Sankyo Co., Ltd.,
Nippon Boehringer Co., Ltd., Mitsubishi
Tanabe Corporation, Tokushima Data
Service Co., Ltd. and Astellas Pharm
Inc.). Akio Kuroda received a speaker fee
(Nippon Eli Lilly Japan K.K.)
Munehide Matsuhisa* , Akio Kuroda
Diabetes Therapeutics and Research




1. Namba M, Iwakura T, Nishimura R,
et al. The current status of treatment-
related severe hypoglycemia in
Japanese patients with diabetes
mellitus: a report from the committee
on a survey of severe hypoglycemia in
the Japan Diabetes Society. J Diabetes
Investig 2018; 9: 642–656.
2. Lee AK, Lee CJ, Huang ES, et al. Risk
factors for severe hypoglycemia in
black and white adults with diabetes:
the Atherosclerosis Risk in
Communities (ARIC) study. Diabetes
Care 2017; 40: 1661–1667.
3. Lipska KJ, Inzucchi SE, Warton EM,
et al. HbA1c and risk of severe
hypoglycemia in type 2 diabetes. The
Diabetes and Aging Study. Diabetes
Care 2013; 36: 3535–3542.
4. Kilpatrick ES, Rigby AS, Goode K, et al.
Relating mean blood glucose and
glucose variability to the risk of
multiple episodes of hypoglycaemia in
type 1 diabetes. Diabetologia 2007; 50:
2553–2561.
5. Japan Diabetes (JDS)/Japan Geriatrics
Society (JGS) Joint Committee on
Improving Care for Elderly Patients
with Diabetes. Committee Report:
glycemic targets for elderly patients
with diabetes. J Diabetes Investig 2017;
8: 126–128.
6. Gomez AM, Henao DC, Imitola A,
et al. Efficacy and safety of sensor-
augmented pump therapy (SAPT)
with predictive low-glucose
management in patients diagnosed
with type 1 diabetes mellitus
previously treated with SAPT and low
glucose suspend. Endocrinol Diabetes
















1,5-AG, per 5 µg/mL
Nt-proBNP, per log-transformed SD
hs-cTnT, per log-transformed SD
hsCRP, per log-transformed SD
Beta-blockers
Anti-depressants
Family history of diabetes
Medicaid insurance
Education (ref = some college)
High school graduate































Model 1 Model 2 0.5 1 2
Hazard ratio
4
Figure 1 | Adjusted hazard rations and 95% confidence intervals for non-traditional risk factors
for hypoglycemia (n = 1,144; 169 people with hypoglycemia). Model 1 included age, sex and
race. Model 2 included all variables in model 1 plus obesity, fructosamine, diabetes duration,
diabetes medication, renal function and the albumin-to-creatinine ratio. 1.5-AG, 1,5-
anhydroglucitol; ADL, activities of daily living; CHD, coronary heart disease; hsCRP, high-sensitive
C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; IADL, instrumental activities of daily
living; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SD, standard deviation. Reproduced
from the Atherosclerosis Risk in Communities (ARIC) study2 with permission.
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